Prognostic significance of immunohistochemical classification of diffuse large B-cell lymphoma

Hematology

Volumn 14, Issue 2, 2009, Pages 84-89

  Alacacioglu, Inci ^a   Ozcan, Mehmet Ali ^a   Ozkal, Sermin ^a   Piskin, Ozden ^a   Turgut, Nurhilal ^a   Demirkan, Fatih ^a   Ozsan, Guner Hayri ^a   Kargi, Aydanur ^a   Undar, Bulent ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

bcl 2; bcl 6; CD10; Lymphoma; mum 1; Prognosis

Indexed keywords

ANTHRACYCLINE; BCL2 RELATED PROTEIN A1; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; INTERFERON REGULATORY FACTOR 4; PEROXIDASE; PROTEIN BCL 6; RITUXIMAB;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER CLASSIFICATION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EVENT FREE SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; LARGE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN ARRAY ANALYSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 66949115060     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453309X385205     Document Type: Article

References (31)

1. Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol 2001; 13: 325-334.
2. Sjö LD, Poulsen CB, Hansen M, Müller MB, Ralfkiaer E. Profiling of diffuse large B-cell lymphoma by immunohistochemistry: identification of prognostic subgroups. E Eur J Haematol 2007; 79: 501-507.
3. Gascoyne RD. Emerging prognostic factors in diffuse large B cell lymphoma. Curr Opin Oncol 2004; 16: 436-441.
4. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B cell lymphoma identified by gene expression profiling. Nature 2000; 40: 3503-3511.
5. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947.
6. Chang CC, McClintock S, Cleveland RP, Trzpuc T, Vesole DH, Logan B et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004; 28: 464-470.
7. Dogan A, Bagdi E, Munson P, Isaacson PG. CD10 and Bcl-6 expression in parafin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 2000; 24: 846-852.
8. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
9. A clinical evaluation of the International Lymphoma: The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909-3918.
10. Uherova P, Ross CW, Schnitzer B, Singleton TP, Finn WG. The clinical significance of CD10 antigen expression in diffuse large B cell lymphoma. Am J Clin Pathol 2001; 115: 582-588.
11. - diffuse large B-cell lymphoma: identification of a high-risk subset with coexpression of CD10 and bcl-2. Am J Clin Pathol 2001; 116: 183-190.
12. Takeshita M, Iwashita A, Kurihara K, Ikejiri K, Higashi H, Udoh T et al. Histologic and immunohistologic findings and prognosis of 40 cases of gastric large B-cell lymphoma. Am J Surg Pathol 2000; 24: 1641-1649.
13. Ohshima K, Kawasaki C, Muta H, Muta K, Deyev V, Haraoka S et al. CD10 and Bcl10 exppression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. Histopathology 2001; 39: 156-162
14. Falini B, Mason DY. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: Clinical value of their detection by immunocytochemistry. Blood 2002; 99: 409-426.
15. Cattoretti G, Chang CC, Cechova K, Zhang J, Ye BH, Falini B et al. BCL-6 protein is expressed in germinal-center B cells. Blood 1995; 86: 45-53.
16. Colomo L, López-Guillermo A, Perales M, Rives S, Martínez A, Bosch F et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78-84.
17. Barrans SL, O'Connor SJ, Evans PA, Davies FE, Owen RG, Haynes AP et al. Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol 2002; 117: 322-332.
18. Linderoth J, Ehinger M, Akerman M, Cavallin-Stahl E, Enblad G, Erlanson M, Jerkeman M. Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma. Eur J Haematol 2007; 79: 146-149.
19. Falini B, Fizzotti M, Pucciarini A, Bigerna B, Marafioti T, Gambacorta M et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000; 95: 2084-2092.
20. Natkunam Y, Warnke RA, Montgomery K, Falini B, van de Rijn M. Analysis of MUM1/IRF4 protein ekspression using tissue microarrays and immunohistochemistry. Mod Pathol 2001; 14: 686-694.
21. Zhang A, Ohshima K, Sato K, Kanda M, Suzumiya J, Shimazaki K et al. Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas. Pathol Int 1999; 49: 1043-1052.
22. Llanos M, Alvarez-Argüelles H, Alemán R, Oramas J, Diaz-Flores L, Batista N. Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma. Med Oncol 2001; 18: 15-22.
23. Rantanen S, Monni O, Joensuu H, Franssila K, Knuutila S. Causes and consequences of BCL2 overexpression in diffuse large B-cell lymphoma. Leuk Lymphoma 2001; 42: 1089-1098.
24. Iqbal J, Sanger WG, Horsman DE, Rosenwald A, Pickering DL, Dave B et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell like diffuse large B-cell lymphoma. Am J Pathol 2004; 165: 159-166.
25. Berglund M, Thunberg U, Amini RM, Book M, Roos G, Erlanson M et al. Evaluation of immunophenotype in diffuse large B cell lymphoma and its impact on prognosis. Mod Pathol 2005; 18: 1113-1120.
26. Haarer CF, Roberts RA, Frutiger YM, Grogan TM, Rimsza LM. Immunohistochemical Classification of De Novo, Transformed, and Relapsed Diffuse Large B-Cell Lymphoma Into Germinal Center B-Cell and Nongerminal Center B-Cell Subtypes Correlates With Gene Expression Profile and Patient Survival. Arch Pathol Lab Med 2006; 130: 1819-1824.
27. de Jong D, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Lee A et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications-a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007; 25: 805-812.
28. Muris JJ, Meijer CJ, Vos W, van Krieken JH, Jiva NM, Ossenkoppele GJ et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 2006; 208: 714-723.
29. Nyman H, Adde M, Karjalainen-Lindsberg ML, Taskinen M, Berglund M, Amini RM et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007; 109: 4930-4935.
30. Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101: 4279-4284.
31. Winter JN, Weller EA, Horning SJ, Krajewska M, Variakojis D, Habermann TM et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: A prospective correlative study. Blood 2006; 107: 4207-4213.